Six Questions For Merck's Stein On Beating The Competition And Staying Relevant in Diabetes
This article was originally published in Scrip
Executive Summary
During the European Association for the Study of Diabetes meeting in Stockholm this week, the severity of the current disease crisis was impressed upon delegates at every turn. Few presentations failed to include dire warnings of the increasing diabetes epidemic, followed by reminders that over half of those diagnosed with the disease are inadequately treated on current therapies.
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.